Page 24 - நெப்டியூன் ஆரோக்கியம் தீர்வுகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Neptune Wellness Solutions Inc Closes US$55 Million Registered Direct Offering
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neptune Wellness Solutions Inc
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (TSX: NEPT), a diversified and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, today announced that an independent arbitrator engaged to resolve a commercial dispute between Neptune and Azpa Pharmaceuticals Pty. Ltd. ("Azpa") rendered a decision in favor of Neptune, awarding Neptune its full claimed damages, legal fees, and interest of roughly CAD$8M.
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Neptune Wellness Solutions Inc. third-quarter earnings conference call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session.
[Operator instructions] Please be advised that today s conference is being recorded. [Operator instructions] I would now like to hand the conference over to your host, Ms. Megan McGrath. Thank you.
Please go ahead.
Unknown speaker
Good morning, everyone, and thank you for joining us. Yesterday afternoon, we issued a press release, announcing our results for the third quarter of fiscal 2021. We also issued our management discussion and analysis, and consolidated financial statements. These documents have been filed with the Canadian Securities and Regulatory Authorities of the U.S.
(1)
BASEL (dpa-AFX) - Today s Daily Dose brings you news about temporary suspension of bluebird bio s gene therapy trials in sickle cell disease, Sesen Bio s regulatory catalyst for this year, partial hold on Cortexyme s open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer s disease, and expanded FDA approval of Novartis Entresto.
Read on.
1. Sickle Cell Disease Trial Blues For bluebird bio
Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company s LentiGlobin gene therapy trials for sickle cell disease were temporarily suspended after two cases of cancer were reported in study participants.
vimarsana © 2020. All Rights Reserved.